Turkish Version of The Diabetes Quality of Life Brief Clinical Inventory Validity and Reliability

This study aims to develop Turkish version of the Diabetes Quality of Life Brief Clinical Inventory (DQL-BCI) and to perform validity and reliability evaluations.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus Autoimmune Diseases Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Bitlis Eren University

Bitlis, 13000, Turkey (Türkiye)

About this study

The study will be carried out in two phases: DQL-BCI will be translated into Turkish and adapted to the cultural context, and the reliability and validity of the Turkish version of DQL-BCI will be investigated. The translation process will be performed in accordance with generally accepted international principles of translation and cultural adaptation of measurement tools. At least 150 subjects with type 2 diabetes will complete the Turkish version of DQL-BCI, the EQ-5D-3L questionnaire and the SF-12 quality of life questionnaire. The examination will provide information about the reliability and the construct validity of the studied tool.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aged between 18-65 years old
Diagnosed with diabetes for one year or more (Type 1 or Type 2)
Literacy
Being on at least one anti-diabetes medication

Exclusion criteria

Not willing to participate in the study

Treatment and study plan

Questionnaire

Other

The original form of the Diabetes Quality of Life-Brief Clinical Inventory was first developed in 1999 to establish a valid and reliable form of diabetes-specific quality of life. Inventory items were developed to address the issues that have the greatest impact on assessing patient self-care behaviors and satisfaction with diabetes care. Items are ranked on a 5-point Likert scale and are in two general formats. One format includes satisfaction with treatment and quality of life and is scored from 1 (very satisfied) to 5 (not very satisfied). The second format includes the frequency of adverse effects of diabetes itself or diabetes treatment and offers response options from 1 (never) to 5 (always). Therefore, higher scores on the DQL-BCI items and subscales include negative values indicating problem frequency or dissatisfaction. In order to use the DQL scale more efficiently in clinics, Burroughs et al. organized the 15-item DQL-BCI in 2004.

Primary outcomes

The Diabetes Quality of Life - Brief Clinical Inventory

Time frame: 1 week

The questionnaire consists of 15 questions, with no grouping into subscales or domains. Items are in two general formats. The first format is about the frequency of negative impacts of diabetes or odiabetes treatment and provides response options from "never" to "all the time". The second format is about the satisfaction with the treatment and QoL, and patients provide answers by selecting from "very satisfied" to "very dissatisfied". Answers to each question correspond to a score of 1-5, and 1 is the lowest score of a given parameter and 5 is the highest. The total score is the sum of scores of individual questions. The scoring ranges from 15 (the worst assessment of QoL) to 75 points (the best assessment of QoL).

Sponsors and collaborators

Lead sponsor

İlke KARA, PT

Other

Collaborators

Bitlis Eren University

Registry information

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Jun 7, 2022
Registry last updated: Sep 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed